EVEROLIMUS vs IRESSA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 6, 2026·How we rate

Possible drug interaction. EVEROLIMUS and IRESSA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EVEROLIMUS	IRESSA
Rating	72/100	70/100
Pharmacy pays	~$219.28 /30	—
Type	RX	RX
Active ingredient	EVEROLIMUS	GEFITINIB
Manufacturer	Biocon Pharma	Astrazeneca
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	None
Half-life	about 30 hours (mean terminal elimination half-life)	—
Treats	—	Non-Small-Cell Lung Carcinoma

everolimus iressa

Rating

72/100

70/100

Pharmacy pays

~$219.28 /30

—

Type

Active ingredient

EVEROLIMUS

GEFITINIB

Manufacturer

Biocon Pharma

Astrazeneca

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Half-life

about 30 hours (mean terminal elimination half-life)

—

Treats

—

Non-Small-Cell Lung Carcinoma

Frequently asked questions

Which is better-rated, Everolimus or Iressa?

By our independent rating, Everolimus scores higher — 3.6 vs 3.5 out of 5 for Iressa. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Everolimus and Iressa?

Everolimus contains Everolimus, while Iressa contains Gefitinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.